SPINT2 controls SARS-CoV-2 viral infection and is associated to disease severity
Abstract COVID-19 outbreak is the biggest threat to human health in recent history. Currently, there are over 1.5 million related deaths and 75 million people infected around the world (as of 22/12/2020). The identification of virulence factors which determine disease susceptibility and severity in different cell types remains an essential challenge. The serine protease TMPRSS2 has been shown to be important for S protein priming and viral entry, however, little is known about its regulation. SPINT2 is a member of the family of Kunitz type serine protease inhibitors and has been shown to inhibit TMPRSS2. Here, we explored the existence of a co-regulation between SPINT2/TMPRSS2 and found a tightly regulated protease/inhibitor expression balance across tissues. We found that SPINT2 negatively correlates with SARS-CoV-2 expression in Calu-3 and Caco-2 cell lines and was down-regulated in secretory cells from COVID-19 patients. We validated our findings using Calu-3 cell lines and observed a strong increase in viral load after SPINT2 knockdown. Additionally, we evaluated the expression of SPINT2 in datasets from comorbid diseases using bulk and scRNA-seq data. We observed its down-regulation in colon, kidney and liver tumors as well as in alpha pancreatic islets cells from diabetes Type 2 patients, which could have implications for the observed comorbidities in COVID-19 patients suffering from chronic diseases..
Medienart: |
Preprint |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
bioRxiv.org - (2020) vom: 30. Dez. Zur Gesamtaufnahme - year:2020 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Alvarez, Carlos Ramirez [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
doi: |
10.1101/2020.12.28.424029 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
XBI019593384 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | XBI019593384 | ||
003 | DE-627 | ||
005 | 20230429085743.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201229s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1101/2020.12.28.424029 |2 doi | |
035 | |a (DE-627)XBI019593384 | ||
035 | |a (DE-599)biorXiv10.1101/2020.12.28.424029 | ||
035 | |a (biorXiv)10.1101/2020.12.28.424029 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | |a 570 |q DE-84 | |
100 | 1 | |a Alvarez, Carlos Ramirez |e verfasserin |4 aut | |
245 | 1 | 0 | |a SPINT2 controls SARS-CoV-2 viral infection and is associated to disease severity |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract COVID-19 outbreak is the biggest threat to human health in recent history. Currently, there are over 1.5 million related deaths and 75 million people infected around the world (as of 22/12/2020). The identification of virulence factors which determine disease susceptibility and severity in different cell types remains an essential challenge. The serine protease TMPRSS2 has been shown to be important for S protein priming and viral entry, however, little is known about its regulation. SPINT2 is a member of the family of Kunitz type serine protease inhibitors and has been shown to inhibit TMPRSS2. Here, we explored the existence of a co-regulation between SPINT2/TMPRSS2 and found a tightly regulated protease/inhibitor expression balance across tissues. We found that SPINT2 negatively correlates with SARS-CoV-2 expression in Calu-3 and Caco-2 cell lines and was down-regulated in secretory cells from COVID-19 patients. We validated our findings using Calu-3 cell lines and observed a strong increase in viral load after SPINT2 knockdown. Additionally, we evaluated the expression of SPINT2 in datasets from comorbid diseases using bulk and scRNA-seq data. We observed its down-regulation in colon, kidney and liver tumors as well as in alpha pancreatic islets cells from diabetes Type 2 patients, which could have implications for the observed comorbidities in COVID-19 patients suffering from chronic diseases. | ||
700 | 1 | |a Sharma, Ashwini Kumar |e verfasserin |4 aut | |
700 | 1 | |a Kee, Carmon |e verfasserin |4 aut | |
700 | 1 | |a Thomas, Leonie |e verfasserin |4 aut | |
700 | 1 | |a Boulant, Steeve |e verfasserin |4 aut | |
700 | 1 | |a Herrmann, Carl |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2020) vom: 30. Dez. |
773 | 1 | 8 | |g year:2020 |g day:30 |g month:12 |
856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.12.28.424029 |z kostenfrei |3 Volltext |
912 | |a GBV_XBI | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |j 2020 |b 30 |c 12 | ||
953 | |2 045F |a 570 |